Vigilant Biosciences has appointed Michael Donovan, MD, PhD, as the its new chief clinical officer.
Dr. Donovan will be part of the executive management team and is responsible for advancing Vigilant's oral cancer product line. He received his medical degree from the University of Medicine and Dentistry of New Jersey and his doctorate in cell and developmental biology from Rutgers University.
Vigilant has also created a Scientific Advisory Board of five members to advise the company's research and development efforts.
